Compositions for the inhibition of
The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH)enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.
1. A method of reducing the development of giardiasis in a subject, comprising administering a composition exhibiting a bile-salt hydrolase activity to a subject;
wherein said composition is chosen from:
a composition comprising at least one bile-salt hydrolase (BSH) enzyme, wherein said BSH enzyme has an amino acid sequence at least 95% identical to SEQ ID NO: 6;
a composition comprising a lactic acid bacterium able to secrete at least one BSH enzyme, wherein said BSH enzyme has an amino acid sequence at least 95% identical to SEQ ID NO: 6, and wherein said lactic acid bacterium is not Lactobacillus johnsonii La1, Lactobacillus acidophilus, Bifidobacterium bifidum or Bifidobacterium infantis ; and
a combination thereof;
wherein said bile-salt hydrolase activity is determined by the detection of the presence of glycine or taurine liberated from conjugated bile salts, of cholic acid, of deoxycholic acid and/or of chenodeoxycholic acid.
2. The method according to claim 1 , wherein said bile-salt hydrolase activity is associated with the presence of at least one bile-salt hydrolase (BSH) enzyme.
3. The method according to claim 1 , wherein said administered composition comprises a lactic acid bacterium able to secrete a BSH, wherein said bacterium is selected from:
Lactobacillus , but not Lactobacillus johnsonii La1 or Lactobacillus acidophilus ; and
Bifidobacterium , but not Bifidobacterium bifidum or Bifidobacterium infantis.
4. The method according to claim 3 , wherein said lactic acid bacterium is a Lactobacillus chosen from the group consisting of:
Lactobacillus johnsonii , but not Lactobacillus johnsonii La1;
Lactobacillus gasseri; and
Lactobacillus acidophilus , but not Lactobacillus acidophilus La10; and
Lactobacillus reuteri.
5. The method according to claim 3 , wherein said Lactobacillus is chosen from the group consisting of the bacterial strains:
Lactobacillus johnsonii filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4885, on Aug. 7, 2014; and
Lactobacillus gasseri filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4884, on Aug. 7, 2014.
6. The method according to claim 1 , wherein the subject is a human being.
7. The method according to claim 1 , wherein the subject is a pig or cow.
8. A method of reducing the development of giardiasis in a subject, comprising administering a composition exhibiting a bile-salt hydrolase activity to a subject;
wherein said composition comprises a lactic acid bacterium able to secrete at least one BSH enzyme, and wherein said lactic acid bacterium is not Lactobacillus johnsonii La 1, Lactobacillus acidophilus, Bifidobacterium bifidum or Bifidobacterium infantis;
wherein said bile-salt hydrolase activity is determined by the detection of the presence of glycine or taurine liberated from conjugated bile salts, of cholic acid, of deoxycholic acid and/or of chenodeoxycholic acid.
9. The method according to claim 8 , wherein said bile-salt hydrolase activity is associated with the presence of at least one bile-salt hydrolase (BSH) enzyme.
10. The method according to claim 9 , wherein said BSH enzyme is a BSH from prokaryotes.
11. The method according to any claim 8 , wherein said BSH enzyme comprises an amino acid sequence having at least 95% identity with an amino acid sequence chosen from the group consisting of: Lactobacillus johnsonii La1 BSH-12 (SEQ ID NO: 1), Lactobacillus johnsonii La1 BSH-47 (SEQ ID NO: 2), Lactobacillus johnsonii La1 BSH-56 (SEQ ID NO: 3), Lactobacillus gasseri BSH-A (SEQ ID NO: 4), Lactobacillus gasseri BSH-B (SEQ ID NO: 5), Lactobacillus johnsonii DPC 6026 BSH (SEQ ID NO: 6), Lactobacillus johnsonii DPC 6026 BSH (SEQ ID NO: 7), and Lactobacillus johnsonii DPC 6026 BSH (SEQ ID NO: 8).
12. The method according to claim 8 , wherein said administered composition comprises a lactic acid bacterium able to secrete a BSH, wherein said bacterium is selected from:
Lactobacillus , but not Lactobacillus johnsonii La1 or Lactobacillus acidophilus ; and
Bifidobacterium , but not Bifidobacterium bifidum or Bifidobacterium infantis.
13. The method according to claim 12 , wherein said lactic acid bacterium is a Lactobacillus chosen from the group consisting of:
Lactobacillus johnsonii , but not Lactobacillus johnsonii La1;
Lactobacillus gasseri ; and
Lactobacillus acidophilus , but not Lactobacillus acidophilus La10; and
Lactobacillus reuteri.
14. The method according to claim 12 , wherein said Lactobacillus is chosen from the group consisting of the bacterial strains:
Lactobacillus johnsonii filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4885, on Aug. 7, 2014; and
Lactobacillus gasseri filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4884, on Aug. 7, 2014.
15. The method according to claim 8 , wherein the subject is a human being.
16. The method according to claim 8 , wherein the subject is a pig or cow.
17. A method of reducing the development of giardiasis in a subject, comprising administering a composition exhibiting a bile-salt hydrolase activity to a subject;
wherein said composition:
comprises a lactic acid bacterium able to secrete at least one BSH enzyme, wherein said BSH enzyme has an amino acid sequence at least 95% identical to SEQ ID NO: 6, and wherein said lactic acid bacterium is not Lactobacillus johnsonii La1, Lactobacillus acidophilus, Bifidobacterium bifidum or Bifidobacterium infantis;
wherein said bile-salt hydrolase activity is determined by the detection of the presence of glycine or taurine liberated from conjugated bile salts, of cholic acid, of deoxycholic acid and/or of chenodeoxycholic acid.
18. The method according to claim 17 , wherein said bile-salt hydrolase activity is associated with the presence of at least one bile-salt hydrolase (BSH) enzyme.
19. The method according to claim 17 , wherein said administered composition comprises a lactic acid bacterium able to secrete a BSH, wherein said bacterium is selected from:
Lactobacillus , but not Lactobacillus johnsonii La1 but not Lactobacillus acidophilus ; and
Bifidobacterium , but not Bifidobacterium bifidum or Bifidobacterium infantis.
20. The method according to claim 19 , wherein said lactic acid bacterium is a Lactobacillus chosen from the group consisting of:
Lactobacillus johnsonii , but not Lactobacillus johnsonii La1;
Lactobacillus gasseri ; and
Lactobacillus acidophilus , but not Lactobacillus acidophilus La10; and
Lactobacillus reuteri.
21. The method according to claim 19 , wherein said Lactobacillus is chosen from the group consisting of the bacterial strains:
Lactobacillus johnsonii filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4885, on Aug. 7, 2014; and
Lactobacillus gasseri filed at CNCM, Institut Pasteur, Paris, France, under reference 1-4884, on Aug. 7, 2014.
22. The method according to claim 17 , wherein the subject is a human being.
23. The method according to claim 17 , wherein the subject is a pig or cow.